Radiation Toxicity Treatment Market to Grow with a CAGR of 5.43% through 2028
Rising awareness
of radiation-induced side effects among patients is expected to drive the
Global Radiation Toxicity Treatment Market growth in the forecast period, 2024-2028.
According to
TechSci Research report, “Radiation Toxicity Treatment Market – Global
Industry Size, Share, Trends, Competition Forecast & Opportunities,
2028”, the Global Radiation Toxicity Treatment Market stood at USD 2.23
billion in 2022 and is anticipated to grow with a CAGR of 5.43% in the forecast
period, 2024-2028.
The Global Radiation Toxicity Treatment Market has been witnessing
remarkable growth in recent years, fueled by a combination of factors that are
reshaping the landscape of cancer treatment and radiation therapy. As the
incidence of cancer continues to rise worldwide, radiation therapy remains a
critical component of cancer care. Increasing Cancer Prevalence: One of the
primary drivers of the radiation toxicity treatment market is the relentless
increase in cancer cases globally. Cancer remains a leading cause of death
worldwide, and the World Health Organization (WHO) estimates that
cancer-related deaths will continue to rise in the coming years. As more
individuals are diagnosed with cancer and opt for radiation therapy as part of
their treatment plan, the demand for effective radiation toxicity treatments
grows in tandem.
Expanding
Utilization of Radiation Therapy: Radiation therapy has become an indispensable
tool in the oncology arsenal. It is used not only as a curative treatment but
also for palliative care and symptom relief in advanced cancer cases. The
increasing adoption of radiation therapy for various cancer types, including
lung, breast, prostate, and brain cancer, is driving the need for radiation
toxicity treatment options. This growing utilization of radiation therapy acts
as a catalyst for the development and expansion of the radiation toxicity
treatment market.
The field of
radiation therapy has witnessed remarkable technological advancements in recent
years. Innovations such as intensity-modulated radiation therapy (IMRT),
stereotactic body radiation therapy (SBRT), and proton therapy have
revolutionized the precision and effectiveness of radiation treatment. These
advanced techniques not only improve the targeting of cancer cells but also
minimize radiation exposure to healthy tissues, reducing the risk of toxicity.
Consequently, the demand for radiation toxicity treatment has surged, as
patients and healthcare providers seek ways to manage treatment-related side
effects more effectively.
Pharmaceuticals
and radioprotective agents have emerged as a crucial segment of the radiation
toxicity treatment market. These agents are designed to protect healthy tissues
from the damaging effects of radiation therapy while enhancing the tumor's
sensitivity to radiation. The development of radioprotective drugs and targeted
therapies represents a significant advancement in the field, as they enable
oncologists to optimize radiation treatment protocols, minimize toxicity, and
improve patient outcomes. The continuous research and development efforts in
this area are expected to further drive market growth. Increased
awareness about the potential side effects of radiation therapy and the
availability of radiation toxicity treatment options are empowering patients to
actively participate in their treatment decisions. Healthcare providers are
also investing in patient education to help individuals make informed choices
about their cancer care.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on "Radiation Toxicity Treatment Market.”
The Global Radiation
Toxicity Treatment Market is segmented into Product, Indication, Radiation, End-user, regional distribution, and company.
Based on the
Product, the Colony Stimulating Factors emerged as the dominant segment in the
global market for Global Radiation Toxicity Treatment Market in 2022. The
primary reason for this is the critical role Colony Stimulating Factors (CSFs)
play in mitigating the effects of radiation-induced toxicity, particularly in
the context of cancer treatment and radiation therapy. Radiation therapy is a
common treatment modality for various cancers, including breast, lung, and
prostate cancer. Since CSFs are a standard part of supportive care for cancer
patients undergoing radiation therapy, they are in high demand in oncology
settings.
Based on the
Indication, the Chronic Radiation Syndrome emerged as the dominant player in
the global market for Global Radiation Toxicity Treatment Market in 2022.
Chronic radiation syndrome typically arises from prolonged or repeated exposure
to ionizing radiation over an extended period. This is often seen in
occupational settings, such as nuclear power plants, radiological laboratories,
and certain industrial environments. Long-term exposure scenarios are more
common than acute radiation incidents, resulting in a higher prevalence of
chronic radiation syndrome cases.
Based on the End
Users, the Hospitals & Clinics emerged as the dominant player in the global
market for Global Radiation Toxicity Treatment Market in 2022. Hospitals,
especially larger medical centers, offer a wide range of comprehensive
healthcare services, including radiation therapy for cancer treatment. Patients
with radiation-induced toxicities often require multidisciplinary care that
spans various medical specialties. Hospitals can provide this comprehensive
care under one roof, making them a natural choice for radiation toxicity
treatment. Hospitals typically see a high volume of patients, including those
undergoing radiation therapy. With the increasing incidence of cancer
worldwide, hospitals are well-equipped to handle a large number of radiation
therapy cases, leading to a higher demand for radiation toxicity treatment
within these facilities.
Patients
undergoing radiation therapy may require ongoing monitoring and adjustments to
their treatment plans. Hospitals can provide the continuity of care needed to
manage radiation-induced side effects and adjust treatment regimens as
necessary. This ensures that patients receive timely and appropriate radiation
toxicity treatment throughout their therapy.
North America
emerged as the dominant player in the global Radiation Toxicity Treatment
Market in 2022, holding the largest
market share. North America boasts a highly advanced and sophisticated
healthcare infrastructure, with state-of-the-art medical facilities, research
institutions, and cutting-edge technology. This infrastructure enables the
region to provide top-quality radiation therapy and radiation toxicity
treatment services, attracting patients not only from within the region but also
from around the world. North America has a relatively high incidence of cancer
cases. This increased prevalence of cancer drives the demand for radiation
therapy as a primary treatment modality. Consequently, there is a greater need
for effective radiation toxicity treatment in the region to manage the side
effects associated with radiation therapy.
In many North
American countries, health insurance coverage is widespread, facilitating
access to radiation therapy and radiation toxicity treatment for a significant
portion of the population. This broad access helps maintain a robust market for
radiation toxicity treatments.
Major companies
operating in Global Radiation Toxicity Treatment Market are:
- Amgen Inc.
- Jubilant Pharma Limited
- Tanner Pharma Group
- Heyl Chemisch-pharmazeutische Fabrik
GmbH & Co. KG
- Recipharm AB
- Mission Pharmacal Company
- Partner Therapeutics, Inc.
- Novartis AG
- Mylan NV
- Coherus Biosciences Inc
Download Free Sample Report
Customers can
also request for 10% free customization on this report.
“The
Global Radiation Toxicity Treatment Market is poised for substantial growth in
the coming years, driven by several key factors. Firstly, the rising prevalence
of cancer worldwide continues to fuel the demand for radiation therapy, making
radiation toxicity treatment a critical component of cancer care. Secondly,
ongoing technological advancements in radiation therapy techniques and
equipment enhance treatment precision, increasing the need for effective
radiation toxicity management. Additionally, the growing awareness of
radiation-induced side effects among patients and healthcare providers is
promoting the adoption of radiation toxicity treatment options. The trend
toward personalized medicine and targeted therapies is further driving the
development of innovative radiation toxicity treatments tailored to individual
patient needs.” said Mr. Karan Chechi, Research Director with TechSci Research,
a research-based management consulting firm.
“Radiation
Toxicity Treatment Market - Global
Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By
Product (Colony Stimulating Factors, Potassium Iodide, Prussian Blue
Diethylenetriamine Pentaacetic Acid, Others), By Indication (Acute Radiation
Syndrome, Chronic Radiation Syndrome), By Radiation Type (Ionizing Radiation,
Non-ionizing Radiation), By End-user (Hospitals & Clinics, Ambulatory Care
Centres, Others) By Region and
Competition”, has evaluated the future growth potential of Global
Radiation Toxicity Treatment Market and provides statistics & information
on market size, structure and future market growth. The report intends to
provide cutting-edge market intelligence and help decision makers take sound
investment decisions. Besides, the report also identifies and analyzes the
emerging trends along with essential drivers, challenges, and opportunities in
Global Radiation Toxicity Treatment Market.
Contact
Mr. Ken Mathews
708 Third
Avenue,
Manhattan, NY,
New
York 10017
Tel:
+1-646-360-1656
Email: [email protected]
Website: www.techsciresearch.com